Oncologists say Amgen Inc.’s experimental ovarian cancer drug trebananib offers little to no benefit in terms of overall survival, leading analysts to predict it has little change of winning approval from drug regulators. Amgen Inc. reported no statically significant improvements in overall survival rates in a late-stage trial pitting trebananib plus chemotherapy against chemotherapy alone in ovarian cancer patients. Statistically significant improvement in overall survival was the secondary goal of the TRINOVA-1 trial, the first of three late-stage studies to evaluate safety and efficacy of the medication. The drug reached its main target, which was to improve survival in ovarian ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.